Morepen Laboratories Ltd.

1984
 
 - Morepen Laboratories Limite Limited Company on December 1st, and
 subsequently converted into a Public Limited Company on March 16,
 1992.
 The Company manufacture CIMC chloride, 7-ADCA acid cephalexin
 Monohydrate, formulation etc.  The bulk drug manufacturing unit
 manufacture life saving drugs such as Ampicillia trihydrate &
 cloxacillin sodium.
 
 - The company undertook to set up a project for manufacture of
 cephalein monohydrate (CPH), CIMC chloride and 7-ADCA with
 capacities,
 72 tpa, 54 tpa and 54 tpa respectively and cephalexin monohydrate.
 
 1993
 
 - The company adapted the M/s. Techquin Elabeissment, Switzerland &
 Technology for launching Laratadine and cisapride.  Formulations
 division was set up.
 
 - The Company undertook to establish facilities for herbal research
 and
 development at Gurgaon with financial assistance from ICICI under
 its
 technology support services programme.
 
 - 18,00,000 shares issued, subscribed & paid up.  34,00,000 No. of
 equity shares of Rs 10 each were issued at a prem. of Rs 15 per
 share
 in November 1992 of which the following were reserved for allotment
 on
 a preferential basis: (1) 1,40,000 shares to employees (24,900
 shares
 taken up); (2) 6,00,000 shares to UTI (all were taken up); (3)
 6,00,000
 shares to LIC (all were taken up); (4) 1,00,000 shares to TDICI (all
 were taken up).  Balance 14,60,000 shares along with 1,15,100 shares
 not taken up by employees issued to the public.
 
 1995
 
 - The Company launched high value high technology products namely
 Cisapride and Loratadine.
 
 - 26,00,000 shares allotted on conversion of `O' interest
 debentures.
 
 1996
 
 - 78,00,000 shares allotted on Rights basis (prop. 1:1; Prem. Rs
 90).
 
 1997
 
 - The Delhi-based Morepen Laboratories is close to entering into a
 tie-up with the US-based $870 million Stryker Corporation for
 marketing
 the US company's medical equipment in the country.
 
 - The company will launch its OTC healthcare product range in
 January.
 It will introduce garlic-based tablets, ginger-based tablets,
 antacids,
 sweeteners and memory tonics, etc.
 
 1998
 
 - Meanwhile, many of the major European generic companies have
 signed
 agreements with Morepen to import bulk drugs.  During the year, the
 company has further expanded its marketing network for exports which
 would help the company to further expand its sales by tapping new
 markets.
 
 - The company also earned the distinction of introducing for the
 first
 time in India two new molecules - Loratadine and Cisapride - in bulk
 and formulation forms owing to its in house R&D facilities.
 
 - During the year the company made its entry into the US market
 following the filing of drug master file of loratadine with USFDA
 which
 was acknowledge and assigned a DMF number.
 
 1999
 
 - MOREPEN Laboratories Ltd has signed an agreement with PARI GmbH of
 Germany for marketing its inhalation systems for respiratory
 diseases
 in the country.  The company has thus become the youngest Indian
 company to obtain this approval from USFDA authorities.
 
 - The company currently has a installed capacity of 6 tonnes per
 annum,
 and in the years to come, around 50 per cent of the company's
 turnover
 is expected to be contributed by this product.
 
 - The company's manufacturing facilities for Loratadine at Parwanoo
 in
 Himachal Pradesh was recently awarded the United States Food and
 Drug
 Authority (USFDA) approval, which would enable it to explore new
 markets.
 
 - Loratadine, manufactured by the company at its bulk drug plant at
 Parwanoo (Himachal Pradesh), is the fifth largest selling drug in
 the
 world with over 50 per cent market share among all anti-hystamines.
 
 - The consumer care division of the company has launched DAB, an
 antacid with fruit flavours.  The other products in the pipeline are
 Sugar Care (a low calorie sweetener), Garlitone, (Garlic tablets),
 Mintina-Peppermint tablets and Slimwell (weight reducing agent).
 
 - It has set up a most modern state-of-the-art plant at Baddi in
 Himachal Pradesh as per the US FDA guidelines and international
 standards.
 
 - Dab, an ayurvedic antacid granule in sachet packaging -- was
 introduced in the market recently.  Morepen is now also planning to
 introduce the same in bottles.
 
 - In the consumer-care product category, the company is all set to
 introduce vitamin products for pregnant women.  Zimvit-P to be
 launched
 in next four months would be for providing the necessary vitamin
 support to the `would-be mothers' and Zimvit-L for supporting the
 post-pregnancy vitamin requirements of the young mothers.
 
 - The company is entering into the segment of generic manufacturing
 and
 has identified at least 20 non-patent high-volume generic products
 and
 the process could begin within the next few months.
 
 - Amongst new bulk drugs to be launched by the company in the near
 future are `Atorvastatin' and `Fluvastatin' (both cholesterol
 reducers), `Paroxetin' (anti-depressant), `Losartan'
 (anti-hypertensive), `Zafirlukast' and `Montelukast' (both
 anti-asthmatic).
 
 - The new products lined up in the OTC segment include hospital
 foods,
 health water, Cold-N-Fever tablets, Vitamin-C tablets and three
 variants of DAB (a fruit-flavoured antacid).
 
 - The company is also planning to launch `Sugar care' (a low calorie
 sweetener), Garlitone (garlic tablets), Mintina (peppermint tablets)
 and slimwell (weight reducing agents).  These products will be
 launched
 within a year's time.
 
 2000
 
 - The company has informed that on February 8th, it would allott
 25,00,000 equity shares of Rs. 10 each at a premium of Rs. 640 per
 share aggregating Rs. 1,625,000,000 on preferential allotment basis
 to
 FI/FIIs/MFs/OCBs and others in accordance with the SEBI Guidelines.
 
 - The Company has decided to split the equity shares of Rs.10 each
 into
 5 shares of Rs.2 each and also formed a compensation committee to
 draft
 a scheme for offering equity shares to employees under ESOS.
 
 - The Company is in the process of entering into a joint venture
 agreement with a US-based company for carrying out research and
 development (R&D) in the area of medicinal biotechnology..
 
 - The Delhi-based Morepen Laboratories has tied up with five leading
 generic companies -- Apotex, Novex Pharma, Genpharm, Novopharm and
 Technilab -- in Canada, among others, for supplying its non-sedative
 anti-histamine, loratadine.
 
 - Shri. K. B. Suri, Chairman cum Managing Director expired on 28th
 October, and Shri Sushil Suri Director has been appointed as
 Chairman
 cum Managing Director.
 
 2001
 
 - The $2000-million, DiaMed AG has formed a technology-cum-marketing
 joint venture with the Delhi-based, Morepen Laboratories.
 
 - Morepan Labs has launched Optimal Rapid Malaria Test Kit -- a
 product
 from DiaMed AG, leading in blood group serology.
 
 - The Company has reissued 17000 No of equity shares of Rs. 2/- each
 from the for feiture Account to its Employees.
          
 -The Company has entered into a strategic manufacturing joint
 venture
 with the US-based Ameritek Inc, a global player in rapid diagnostic
 test kits.
 
 -Morepen Labs has entered into a marketing alliance with Beurer GmbH
 &
 Co to sell a range of diagnostic and therapeutic monitoring systems
 to
 monitor health at home.
 
 2002
 
 -Apollo Hospitals Group and Morepen laboratories Ltd enters into a
 joint venture for the crisis of the emergency services.
 
 -Decides not to buy Coldact, the cold and cough pill from Sun
 Pharmaceuticals.
 
 -Launches 'Dab' a new product in the gastro category.
 
 -Invests Rs.100cr as part of its plan to achieve sales of Rs.200cr in
 five years.
 
 -Creates four SBU's via global generics, medicus,diagnostics and fast
 moving health goods.
 
 -Appoints Mr Vasanth Sivaraman as its Vice-president, corporate
 finance for its Mumbai Office.
 
 -Acquires Lifespring, a chain of health and beauty stores at a
 consideration of Rs.120 million from Total Care Pvt Ltd.
 
 -Acquires Lemolate, a premium brand of Yash Pharma Laboratories Ltd
 in the cough and cold category.
 
 -Hikes its expenditure from more than Rs.30cr for its R & D
 initiatives.
 
 -Increases its production capacity by two times for loratidine to
 around 24 tonne in anticipation of the expected demand from US
 market.
 
 -Appoints Mr Sanjay Suri as the Director on the Board of the
 company.
 
 -Signs Marketing Joint Venture with Italian Diagnostic company, A
 Menarini, to market the latter's glucometer range under the company's
 umbrella in India.
 
 -Members of USFDA approves Loratadine as the Over-the counter Allergy
 Drug.
 
 -Invests Rs.12 cr in Lifespring.
 
 -Mr Karthik Raina quits the Morepen Laboratories.
 
 2003
 
 -Ties up with Analyticon to market urine analysis reagent strips.
 
 -Gets 180-day marketing rights for the drug in the US market.
 
 -Files an international patent under the Patent Cooperation Treaty 
 for manufacturing process of Desloratadine 
 
 -Mr Sanjay Suri and Ms Kanta Suri  resign from their directorship of
 the company.
 
 -BOD of the company approve for the GDR issue.
 
 -Signs an agreement of collaborative research program with National
 Institute of Pharmaceutical Education and Research.  
 
 -Receives clearance from Luxembourg Stock Exchange in respect of
 company's GDR offering.
 
 -Allots 5,000,000 GDR's representing 50,000,000equtiy shares of Rs.2
 each at a price of USD 3.05 per GDR.
 
 -Debt Recovery Tribunal puts hold on the proceedings of the lab's
 $15.25 million GDR issue.
 
 -Extends the financial year by 6 months because of declining sales
 scenario and difficult debt restructuring phase.
 
 -Applies for the international process and product patents for the
 drug Fluvastatin Sodium.
 
 -CL B approves Fixed deposits repayment plan of the company.
 
 -Accomplishes the export order of Loratadine for an amount of $15
 million.
 
 -Bags 15 year supply contract cum licensing agreement from Generix.
 
 -Receives US Food and Drug Administrator approval for active
 pharmaceutical ingredient (API) manufacturing facilities at
 Masulkhana, Himachal Pradesh.
 
 
 2004
 
 - Morepen Labs gets approval for international patent of a new
 crystalline form (VI) of Atorvastatin, a cholesterol-lowering drug.
 
 -The Company received a fresh US Food and Drug Administrator approval
 for its active pharmaceutical ingredient (API) manufacturing
 facilities at Masulkhana, Himachal Pradesh. 
 
 -The company has entered the anti-diabetics market of US with its
 insulin sensitizer-Pioglitazone Hydrochloride (Actos).
 
 -Morepen Labs bags international patent for cholesterol drug.
 
 2005
 
 -Morepen Laboratories second to join the Lipitor Club in USA.
 
 -Morepen Laboratories announces 52 DMF filings for 6 products in EU.
 
 -Morepen registers 52 DMF across 10 European countries.
 
 -The Company announced an increase in its holding in Doctors Morepen
 Ltd (DML), which was earlier, hived off as an Independent Company. 
 
 2006
 
 -Re-appointment of Mr Manoj Joshi & Mr B R Wadhwa as Directors of the
 Company.
 
 2007
 
 -Morepen Lab signs deal with Avenue Capital Group.
 
 2011
 -Morepen gets USFDA approval for Desloratadine.
 
 2013
 
 -Mr. Thomas P. Joshua has joined as the Companys Company Secretary
 and He would also be the new Compliance Officer of the Company.